-
Application of Transfersomes and Ethosomes in Transdermal Drug Delivery
The transfersomes is a self-aggregating vesicle obtained by formulating and improving on the basis of liposomes, also known as flexible nano-liposomes (FNL). It is a lipid carrier obtained by adding surfactants (such as sodium cholate, polysorbate, spaan, sodium deoxycholate, etc.) to liposome materials. It has a high degree of self-deformation and can efficiently pass through skin pores several times smaller than its particle size. The driving force of its penetration into the skin is the hydration gradient and the resulting osmotic pressure difference, which can make the membrane elastically deform and squeeze into the stratum corneum. Widened intercellular space. The particle size of the transfersomes is 90~500nm, the deformability is 5 orders…
-
Oral Nano-drug Delivery System 2
The previous article introduced the relevant information about choosing liposomes and nanoparticles as drug carriers in oral nano-drug delivery systems. This article will continue to introduce the feature of microemulsions, polymers, dendrimers and nano-drug crystals as oral drug carriers. Microemulsion Microemulsion is formed by mixing water phase, oil phase, surfactant and co-surfactant in appropriate proportions, with a particle size of 10~100mpm, transparent or translucent, low viscosity, isotropic thermodynamics and kinetics For a stable oil-water mixing system, there is also literature that the particle size of the microemulsion is 20~200nm. Microemulsions have received extensive attention in recent years because of their significant targeting, sustained-release effects and strong solubilization effects on poorly soluble…
-
Application of Liposome as Drug Carrier
Liposomes are bilayer vesicles composed of phospholipids as the main material, and were first discovered by Bangham, a British scientist. Liposome’s structure is similar to biofilm, also known as artificial biofilm, and is widely used to study the structure and function of biofilm. Liposome used as a drug carrier began in the early 1970s. Due to the advantages of biocompatibility, biodegradability, non-toxicity and non-immunogenicity, liposomes have rapidly developed as new drug dosage forms. After more than 40 years of research, there are currently 12 liposomal preparations on the market. The drugs involved include adriamycin hydrochloride, amphotericin, muramyl-tripeptide, paclitaxel, gentamicin, and cytosine arabinoside, etc. In addition, various types of liposomes are…
-
How Can Phage Display Peptides Be Used in Nano-Drug Carriers
Nanoparticles have received extensive attention as drug carriers in the diagnosis of specific diseases, the detection and monitoring of therapeutic agents, and targeted therapies. The primary strategy for targeting drug carriers is to achieve targeting by utilizing specific recognition capabilities such as antibodies and antigens, ligands and receptors. This type of targeting is often referred to as “active targeting” by functionalizing the surface of the nanoparticle to achieve targeted behavior. Currently, researchers have developed new nanoparticle ligand drug carriers using phage display technology. The phage display technology is to clone a polypeptide or a protein coding gene or target gene fragment into a proper position of a phage coat protein…
